|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Valproic acid and nonalcoholic fatty liver disease: A possible association?显示文摘Valproic acid(VPA) is one of the most prescribed drugs in children with newly diagnosed epilepsy. Weight gain and obesity have been observed as side effects of VPA. These are often linked with other metabolic disturbances such as development of insulin resistance, dyslipidemia, metabolic syndrome(Met S) and nonalcoholic fatty liver disease or nonalcoholic fatty liver disease(NAFLD). NAFLD refers to a group of liver disorders with marked hepatic steatosis. It is associated with an increased incidence of cardiovascular diseases and overall reduced life expectancy. NAFLD occurs in 20%-25% of the general population and it is known to be the most common cause of chronic liver disease. NAFLD therefore represents a major public health issue worldwide. This study reviews and summarizes relevant literature that supports the existence of an association between VPA therapy and the development of NAFLD in children. Long-term VPA-therapy appears to be associated with an increased risk of developing NAFLD. Further studies are needed to clarify the pathogenic mechanisms that lie behind this association and to standardize the options for the use of this drug in overweight patients and in those with risks for developing Met S and NAFLD. | Edoardo Farinelli David Giampaoli Anja Cenciarini Ephraim Cercado Alberto Verrotti | 2015 | World Journal of Hepatology2015，7，9： | 3 |
| 2 | Plasticizer infant nutrition and reproductive health 显示文摘 | Giuseppe Latini Claudio De Felice Alberto Verrotti | 2004 | Reproductive Toxicology2004，19，1： | 1 |
| 3 | Plasticizers, infantnutriti on and Reproductive health 显示文摘 | Giuseppe Latini Claudio De Felice Alberto Verrotti | 2004 | Reproductive Toxicology2004，，： | 1 |
| 4 | Plasticizers, infant nutrition and reproductive health显示文摘 | Giuseppe Latini Claudio De Felice Alberto Verrotti | 2004 | Reproductive Toxicology2004，，1： | 1 |
| 5 | Pharmaeotherapy of spastieity in children with eerebral palsy显示文摘 | Alberto Verrotti Rita Greco Alberto Spalice | 2006 | Pediatr Neurol2006，34，1： | 1 |
| 6 | Benign convulsions associated with mild gastroenteritis: A multicenter clinical study显示文摘 | Alberto Verrotti Giuliana Nanni Sergio AgnstineUi | 2011 | Epilepsy Research2011，93，： | 1 |
| 7 | US in the diagnosis of gastroesophageal reflux in children显示文摘 | Alessandra Savino Cristina Cecamore Maria Matronola Alberto Verrotti Angelika Mohn Francesco Chiarelli Piernicola Pelliccia | 2012 | Pediatric Radiology2012，，： | 1 |
| 8 | Thyroid hormones in children with epilepsy during long-term administration of carbamazepine and valproate 显示文摘 | Alberto Verrotti Melissa Laus Alessandra Scardapane | 2009 | European Journal of Endocrinology2009，160，： | 1 |
| 9 | Plasticizersinfant nutrition and reproductive health显示文摘 | Giuseppe Latini Claudio De Felice Alberto Verrotti | 2004 | Reproductive Toxicology2004，19，1： | 1 |
| 10 | Plasticiz- ers infant nutrition and reproductive health 显示文摘 | Giuseppe Latini Claudio De Feliee Alberto Verrotti | 2004 | Reproductive Toxicology2004，19，1： | 1 |
| 11 | Headache, epilepsy and photosensitivity: how are they connected?显示文摘 | Dorothée G. A. Kasteleijn-Nolst Trenité Alberto Verrotti Alessia Di Fonzo Laura Cantonetti Raffaella Bruschi Francesco Chiarelli Maria Pia Villa Pasquale Parisi | 2010 | The Journal of Headache and Pain2010，，6： | 1 |
| 12 | Plasticizersinfant nutrition and reproductive health显示文摘 | Gius De Felice eppe Latini Claudio Alberto Verrotti | 2004 | Reproductive Toxicology2004，19，1： | 1 |
| 13 | Plasticizers infant nutrition and reproductive health显示文摘 | Giuseppe Latini Claudio De Felice Alberto Verrotti | 2004 | Reproductive Toxicology2004，19，1： | 1 |
| 14 | Plasticizers infant nutrition and reproductive health显示文摘 | Giuseppe Latini Claudio De Felice Alberto Verrotti | 2004 | Reproductive Toxicology2004，19，1： | 1 |
| 15 | Plasticizers,infant nutrition and reproductive health显示文摘 | Latini Giuseppe de Felice Claudio Verrotti Alberto | 2004 | Reproductive Toxicology2004，19，1： | 1 |
| 16 | Clinical spectrum and currently available treatment of typeⅠinterferonopathy Aicardi-Goutières syndrome显示文摘Background Aicardi-Goutières syndrome(AGS)is a genetically determined disorder with a variable phenotype.Since the original description of AGS,advances in gene sequencing techniques have resulted in a significant broadening of the phenotypic spectrum associated with AGS genes,and new clinical pictures have emerged beyond the classic presentation.The aim of this review is to provide a comprehensive analysis of the clinical spectrum of AGS and report currently available treatments and new immunosuppressive strategies.Data sources Literature reviews and original research articles were collected from databases,including PubMed and Clini-calTrials.gov.Relevant articles about AGS were included.Results The involvement of the nervous system certainly represents the major cause of mortality and morbidity in AGS patients.However,other clinical manifestations,such as chilblains,hepatosplenomegaly,and hematological disturbances,may lead to the diagnosis and considerably impact the prognosis and overall quality of life of these patients.Therapeutic approaches of AGS are limited to interventions aimed at specific symptoms and the management of multiple comorbidities.However,advances in understanding the pathogenesis of AGS could open new and more effective therapies.Conclusions The over-activation of innate immunity due to upregulated interferon production plays a critical role in AGS,leading to multi-organ damage with the main involvement of the central nervous system.To date,there is no specific and effective treatment for AGS.New drugs specifically targeting the interferon pathway may bring new hope to AGS patients. | Giovanni Battista Dell'Isola Gianluca Dini Kaleb Logan Culpepper Katherin Elizabeth Portwood Pietro Ferrara Giuseppe Di Cara Alberto Verrotti Mauro Lodolo | 2023 | World Journal of Pediatrics2023，19，7： | 0 |
| 17 | Gastrointestinal and hepatic involvement during COVID-19 pandemic: A focus on pediatric population and possible future implications显示文摘Since the coronavirus disease 2019(COVID-19)pandemic caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has rapidly spread worldwide,there is still limited knowledge about this condition and its natural history.Children have been relatively spared during COVID-19 pandemic but a novel syndrome known as multisystem inflammatory syndrome(MIS-C)has emerged,following a SARS-CoV-2 infection in children and adolescents.This syndrome can lead to shock and multiple organ failure requiring intensive care.Although COVID-19 clinical research focuses on respiratory symptoms,extrapulmonary involvement such as gastrointestinal(GI)and hepatic manifestations should also be considered.In fact,GI and hepatic involvement play an important role among the most common presenting symptoms of both pediatric and adult COVID-19 and MIS-C.This involvement can not only be one of the most common presenting clinical features but also one of the sequelae of these syndromes.Abdominal ultrasonography monitoring could be very useful to identify a potential involvement of the GI tract and liver.Moreover,long-term follow-up is needed and would be essential to define the long-term outcomes of these patients. | Rossella Sica Serena Pennoni Laura Penta Sara Riccioni Giuseppe Di Cara Alberto Verrotti | 2021 | World Journal of Gastroenterology2021，27，40： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员